



Program of the 3rd International Workshop on Waldenström's macroglobulinemia

**October 7-10, 2004
Paris, France**

Thursday, October 7, 2004

Hilton Paris

4:00-7:00 Registration

Lobby

7:30 PM **Welcome Reception**

Dr. Morel (France)
Dr. LeBlond (France)
Dr. Femand (France)
Mr. Ben Rude (IWMF)

Opening Remarks
Opening Remarks
Opening Remarks
Welcome Remarks

Drs. Treon (USA) and Dimopoulos (Greece)
Presentation of ISSWM Achievement Awards

Friday, October 8, 2004

Hilton Paris

7:00-8:00 Breakfast

Session I Genetic basis and pathogenesis of WM

Co-Chairs: Dr. Brouet (France) and Dr. Pilarski (Canada)

| | | |
|---------|-----------------------|--|
| 8:00 AM | Dr. Pilarski (Canada) | Origin of the malignant clone in WM |
| 8:15 AM | Dr. Sahota (UK) | Identifying the WM malignant clone |
| 8:30 AM | Dr. Ocio (Spain)* | Cytogenetics and cell cycle analysis in WM |
| 8:45 AM | Dr. Shaughnessy (USA) | Genomic characterization of WM |

| | | |
|-------------|--------------------------------------|---|
| 9:00 AM | Dr. Fonseca (USA) | <u>Special Lecture:</u> "Genetic basis of WM" |
| 9:15 AM | Dr. Tournilhac (France) | Role of mast cells in WM pathogenesis |
| 9:30 AM | Dr. Santos (Brazil)* | Mast cell-tumor cell interactions in WM |
| 9:45 AM | A. Branagan (USA) and L. Xu (USA) | Receptor-ligand interactions in WM |
| 10:00-10:30 | Dr. Pilarski (Canada) | Wrap-Up and Discussion |
| 10:30-11:00 | Session Break | Refreshments |

Session II Predisposition to Waldenstrom's macroglobulinemia
Chair: Dr. McMaster (USA)

| | | |
|-------------|----------------------------|--|
| 11:00 AM | Dr. Dammacco (Italy) | Hepatitis C predisposition to WM |
| 11:15 AM | Dr. Adamia (Canada)* | Aberrant gene splicing and genetic predispositions in WM |
| 11:30 AM | R. Manning/Z. Hunter (USA) | Characterization of familial WM |
| 11:45 AM | Dr. McMaster (USA) | Update on WM Family Study |
| 12:00-12:30 | Dr. McMaster (USA) | Wrap-Up and Discussion |
| 12:30-2:00 | Session Break | Lunch |

Session III Marginal Zone Lymphoma and Waldenström's macroglobulinemia: Distinct entities or the same?
Chair: Dr. San Miguel (Spain)

| | | |
|-----------|------------------------|---|
| 2:00 PM | Dr. Berger (France) | Clinicopathological features of WM and MZL |
| 2:15 PM | Dr. Pangalis (Greece) | Differential diagnosis of WM and other B-cell disorders |
| 2:30 PM | Dr. Remstein (USA) | Characteristics of LPC vs. non-LPC disorders |
| 2:45 PM | Dr. San Miguel (Spain) | Immunophenotypic and cytogenetic comparison of WM and MZL |
| 3:00-3:30 | Dr. San Miguel (Spain) | Wrap-Up and Discussion |
| 3:30-3:45 | Session Break | Refreshments |

Session IV Evolution of IgM monoclonal gammopathies (MGUS)

Chair: Dr. Kyle (USA)

| | | |
|-----------|---------------------|---|
| 3:45 PM | Dr. Kyle (USA) | Prognostic factors predicting evolution of IgM MGUS |
| 4:00 PM | Dr. Nichols (USA) | Presenting features of IgM MGUS |
| 4:15 PM | Dr. Cesana (Italy)* | Clinical characteristics and outcome of IgM related disorders |
| 4:30 PM | Dr. Morra (Italy) | Prognostic factors for transformation in IgM MGUS |
| 4:30-5:00 | Dr. Kyle (USA) | Wrap-Up and Discussion |

Saturday, October 9, 2004

Hilton Paris

8:00-9:00 Breakfast

Session V Autoimmune related disorders in WM

Chair: Dr. Stone (USA) and Dr. Brouet (France)

| | | |
|-------------|------------------------|--|
| 9:00 AM | Dr. Stone (USA) | Autoantibody activity in WM |
| 9:15 AM | Dr. Fermanand (France) | Autoimmune related disorders in WM |
| 9:30 AM | Dr. Poulain (France) | (Fc γ R)IIIA and IIA polymorphisms in WM and autoimmune disorders |
| 9:45 AM | Dr. Levine (USA) | IgM Neuropathies |
| 10:00 AM | Dr. Gertz (USA) | Cryoglobulinins and cold agglutinins |
| 10:15-10:30 | Dr. Brouet (France) | Wrap-Up and Discussion |
| 10:30-10:45 | Session Break | Refreshments |

Session VI Prognostic Markers in Waldenström's macroglobulinemia

Co-Chairs: Drs. Merlini (Italy) and Morel (France)

| | | |
|-------------|-------------------------------|---|
| 10:45 AM | Dr. Merlini (Italy) | Overview and Report on the International WM Prognostic Index Project |
| 11:00 AM | Dr. Ghobrial (USA)* | Prognostic model for disease specific and overall mortality in newly diagnosed WM |
| 11:15 AM | Dr. Anagnostopoulos* (Greece) | Prognostic value of β_2 microglobulin in WM patients requiring treatment |
| 11:30-12:00 | Dr. Morel (France) | Wrap-Up and Discussion |
| 12:00-1:15 | Session Break | Lunch |

Session VII Therapeutics in WM: Update on nucleoside analogue trials
Chair: Drs. LeBlond (France) and Weber (USA)

| | | |
|-----------|----------------------|--|
| 1:15 PM | Dr. Johnson (UK) | Phase III trial of chlorambucil vs. fludarabine as initial therapy in WM |
| 1:30 PM | Dr. LeBlond (France) | Fludarabine and cytoxan in WM |
| 1:45 PM | Dr. Tam (Australia)* | Fludarabine combination therapy as frontline and salvage therapy in WM |
| 2:00 PM | Dr. Weber (USA) | Cladribine combination therapy in WM |
| 2:15 PM | Dr. Treon (USA) | Rituximab plus Fludarabine in WM |
| 2:30 PM | Dr. Hensel (Germany) | Pentostatin and cytoxan in WM |
| 2:45-3:00 | Dr. Barlogie (USA) | <u>Special Lecture:</u> Do nucleoside analogues really compromise autologous stem cell transplants? |
| 3:00-3:30 | Dr. Weber (USA) | Wrap-Up and Panel Discussion |
| 3:30-3:45 | Session Break | Refreshments |

Session VIII Monoclonal antibody therapy-Predictive factors and observations
Chair: Dr. Dimopoulos (Greece)

| | | |
|-----------|---------------------------|---|
| 3:45 PM | Dr. Dimopoulos (Greece) | Predictive factors for response to Rituximab |
| 4:00 PM | Dr. Hatjiharissi (Greece) | Fc γ RIIIA polymorphisms and response to Rituximab in WM |
| 4:15 PM | Dr. Gertz (USA) | IgM flare after Rituximab in WM |
| 4:30 PM | A. Branagan (USA) | Paradoxical IgM surges following Rituximab and IVIG in WM |
| 4:45-5:00 | Dr. Dimopoulos | Wrap-Up and Discussion |

Session IX Therapeutics in WM: Update on monoclonal antibody trials
Chair: Drs. Kimby (Sweden) and Maloney (USA)

| | | |
|-----------|----------------------|----------------------------------|
| 5:00 PM | Z. Hunter (USA) | Rituximab plus CHOP in WM |
| 5:15 PM | Dr. Treon (USA) | Rituximab plus Thalidomide in WM |
| 5:30 PM | Dr. Owen (UK) | Campath-1H for WM |
| 5:45 PM | Dr. Santos (Brazil)* | Targeting CD52 in WM |
| 6:00-6:15 | Dr. Kimby (Sweden) | Wrap-Up and Panel Discussion |

7:30 PM **Buses depart for dinner reception**

Sunday, October 10, 2004

Hilton Paris

8:00-9:00 Breakfast

Session X Therapeutic initiatives in WM: Part I
Chair: Dr. Fermand (France)

- 9:00 AM Dr. Dimopoulos (Greece) Thalidomide based therapies for WM
9:15 AM Dr. Dreger (Germany) Strategies for improving auto
transplants outcomes in WM
9:30 AM Dr. Munshi (USA) Biologically based therapies for WM
9:45-10:00 Dr. Maloney (USA) **Special Lecture:** "Novel approaches
to transplant therapy for indolent
lymphomas"
10:00-10:15 Dr. Fermand (USA) Wrap-Up and Panel Discussion

Session XI Therapeutics Initiatives for WM: Part II
Chair: Dr. Gertz (USA)

- 10:15 AM Dr. Gertz (USA) Genasense therapy in WM
10:30 AM Dr. Treon (USA) Velcade therapy in WM
10:45 AM Dr. Tournilhac (France) Gleevec as a therapy for WM
11:00 AM Dr. Santos (Brazil)* Sildenafil as a therapy for WM
11:15 AM Dr. Le Gouill (France)* Targeting Mcl-1 and VEGF in WM
11:15-11:30 Dr. Gertz (USA) Wrap-Up and Discussion
11:30-12:00 Session Break Refreshments

Session XII Clinical and Laboratory Observations in WM
Chair: Dr. Emmanouilides (Greece)

- 12:00 PM Dr. Konduri (USA)* Osteoclast activating factors in plasma
cell dyscrasias
12:15 PM Dr. Treon (USA) Hypogammaglobulinemia in WM
12:30 PM Z. Hunter (USA) CD5, CD10, and CD23 in WM
12:45 PM Dr. Menke (USA)* Assessing hyperviscosity with retinal
laser doppler in WM
1:00 PM Dr. Tassone (Italy) Novel Murine SCID-hu Model for WM

1:15 -1:30 Dr. Emmanouilides Wrap-Up and Discussion
1:30-4:00 Consensus Panels Box lunches to be provided

Session XIII Consensus Discussion on Therapeutics in WM
Co-Chairs: Dr. Gertz (USA) and Treon (USA)

1:30-3:00 Open discussion on updating therapy recommendations for WM

Session XIV Consensus Discussion on Response Criteria in WM
Co-Chairs: Drs. Kimby (Sweden) and Blade (Spain)

3:00-4:00 Open discussion on updating response criteria for WM

4:00 PM Meeting adjourned by chairs

6:30 PM Buses depart for Closing Ceremonies and Dinner Reception

Closing Address

Dr. Anders Waldenstrom (Sweden)

"Reflections on the life of my father, Jan Waldenstrom"

*Young Investigator Award Recipient; Sponsored by the
International Waldenstrom's Macroglobulinemia Foundation.